On 18 March 2020 the Nanjing Intermediate People's Court (court) ruled in favor of Yangtze River Pharmaceutical Group and its subsidiary (Yangtze Pharma) in an abuse of dominance case against its suppliers of active pharmaceutical ingredients (API). The court awarded the plaintiffs a record amount of damages as compensation for the anti-competitive conduct: CN¥68.8 million (close to US$10 million). This judgment is expected to encourage more companies to come forward and bring antitrust lawsuits before the Chinese courts.